Phase 2 N=20 Pilot Study of Open-label Placebo to Treat Major Depressive Disorder
Major Depressive Disorder
Primary: Feasibility — 33 screens
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=39 Characterization of Placebo Responses in Stable Asthma
Asthma Placebo Effects
Primary: Change in FEV1 — 20.1; 7.5; 7.3; 7.1 percentage change in FEV1
Phase 4 N=54 Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
Major Depressive Disorder
Primary: Hamilton Rating Scale for Depression — 10.79; 15.30; 12.75 units on a scale
Phase 4 N=82 Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial
Chronic Low Back Pain
Primary: Change in Pain Assessed by Visual Analogue Scale (VAS) — -0.03; -0.10; -0.21 percentage of change in pain
N/A N=64 Effects of Open-label Placebos on COVID-related Psychological Health
Stress · Anxiety · Depression
Primary: COVID-19 Related Stress — 34.93; 35.13; 26.24; 32.37 score on a scale
Phase 4 N=94 Placebo In Chronic Back Pain (Phase 2)
Chronic Low Back Pain
Primary: Percent Change in Pain Assessed by Visual Analogue Scale (VAS) — -0.0145; -0.2082; -0.1109 percentage of pain change
Phase 4 N=80 Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence
Medication Adherence
Primary: Medication Adherence — 85.36; 86.79; 81.93; 86.09 Percentage
N/A N=23 Molecular and Functional PET-fMRI Measures of Analgesia in Migraine
Migraine · Healthy
Primary: Visual Analogue Scale (VAS) 0-10 Pain Rating — 4.3; 7.2 units on a scale
Phase 2 N=110 The Mechanisms of Manual Therapy in the Treatment of Low Back Pain
Low Back Pain
Primary: Believability of Placebo — 67; 37; 78 percentage of participants — p=<0.01
N/A N=31 Efficacy of Open Label Placebo in Children With FGIDs
Functional Abdominal Pain · Functional Dyspepsia · Irritable Bowel Syndrome
Primary: The Primary Outcome Measure Was Mean Daily Pain — 39.9; 45.14 pain scale by VAS in mm — p=<0.03
N/A N=60 A Crossover Study on the Blinding Effect of a New Pragmatic Placebo Needle
Device Ineffective
Primary: Proportion of Volunteers'Perception of Needle Penetration Between the Pragmatic Placebo Needle and Real Needle. — 1; 0; 29; 30 participants — p=>0.05
N/A N=308 Effects of Open-label vs Double-blind Treatment in IBS
Irritable Bowel Syndrome · Placebo Effect · Placebos
Primary: Change in Irritable Bowel Syndrome - Symptom Severity Score (IBS-SSS) From Baseline to Six Weeks. — 74.6; 94.6; 56.4; 90.8 score on a scale
N/A N=74 The Role of Partial Reinforcement in the Long Term Management of Insomnia
Primary Insomnia
Primary: Overall Average Sleep Continuity Profile — 28.8; 33.8; 19.1; 20.7 minutes
N/A N=188 Sleep Without Insomnia or The Use of Chronic Hypnotics
Sleep Initiation and Maintenance Disorders
Primary: Rates of Hypnotic Discontinuation — 64; 52 Participants — p=.039
Phase 4 N=76 The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
Episodic Migraine
Primary: Change in Headache Intensity — -47.6; -20.7 percent change
Phase 4 N=76 Neurobiological Underpinnings of Placebo Response in Depression
Depression
Primary: HAM-D 32 — 33.2; 16.50; 16.00; 16.7 Total score
Phase 4 N=30 Pain Expectations in Subjects With Osteoarthritis
Osteoarthritis
Primary: Resting Pupil Diameter — 64; 72; 69; 66.9 mm — p=0.540
Phase 1 N=57 Placebo-controlled Trial of Transdiscal Radiofrequency Annuloplasty
Lower Back Pain
Primary: Physical Function — 62.04; 48.67 units on a scale
N/A N=18 A Placebo-Controlled Effectiveness in INPH Shunting (PENS) Trial
Idiopathic Normal Pressure Hydrocephalus (INPH)
Primary: Change in Gait Velocity — 0.28; 0.04 meters per second — p=0.071
Phase 4 N=35 Placebo Controled Clinical Trial Using Topiramate To Treat Posttraumatic Stress Disorder (PTSD) Patients.
Posttraumatic Stress Disorder
Primary: Clinician Administered Posttraumatic Stress Disorder Scale — 30.41; 35.78 Total CAPS score — p=0.0076
Phase 3 N=747 Randomized, Double-Blind, Placebo-Controlled Trial Of Pregabalin In Patients With Fibromyalgia.
Fibromyalgia
Primary: Change From Baseline in Mean Pain Score at Endpoint (Up to Week 14) — -0.73; -1.06; -1.29; -0.96 Units on a scale — p=0.2361
Phase 3 N=122 Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
Breast Cancer · Neutropenia
Primary: The Duration in Days of Grade 4 (Severe) Neutropenia Observed in Chemotherapy Cycle 1 in Comparison to Placebo — 1.3; 3.9 days
Phase 3 N=498 Randomized, Double-Blind, Placebo-Controlled Study Of Pregabalin In Patients With Fibromyalgia
Fibromyalgia
Primary: Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline — -1.03; -1.48 Scores on a…
Phase 4 N=4 Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance
Expectancy Versus Pharmacotherapy Effect of Adderall
Primary: Number of Participants Consistently Attending and Completing Four Neuroimaging Sessions — 4; 4; 4; 4 Participants
Phase 4 N=60 Self-Assessment Method for Statin Side-effects Or Nocebo
Adverse Effects · Cardiovascular Diseases · Hyperlipidemias
Primary: Mean Symptom Scores Across Statin, Placebo and no Treatment Periods — 16.3; 15.4; 8.0 units on a scale
N/A N=287 Examining the Effectiveness of Cognitive Training
Cognitive Change
Primary: Proportion of Correct Targets Identified Minus False Identifications in the n-Back Task — .80; .70; .68; .21 score on a scale
N/A N=205 Evaluating the Role of Expectations in Response to Caffeine Consumption: An RCT
Caffeine · Affect · Cognitive Ability, General
Primary: Mood State Score on POMS-2 Test — 2.63; 14.08; 2.19; 2.54 units on a scale
Phase 2 N=37 Neuropeptide Treatment for Hot Flushes During the Menopause
Menopausal Flushing
Primary: Total Number of Hot Flushes During the Final Week of Each 4 Weeks Treatment Period — 19.35; 49.01 hot flushes — p=<0.0001
Phase 3 N=60 Prometa Protocol for Alcohol Dependence
Alcohol Dependence
Primary: Percent Subjects Completely Abstinent — 44; 19; 33; 71 percent of participants — p=0.03
Phase 1 N=18 Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
Non-small Cell Lung Cancer · Pancreatic Cancer · Colorectal Cancer
Primary: Change From Baseline in Cancer-Related Cachexia Symptom Assessment in Appetite Score at Week 4 in Part A — 2.45; 1.84 Units on a Scale